Mereo BioPharma Group PLC ADR (NASDAQ:MREO) — Market Cap & Net Worth
Market Cap & Net Worth: Mereo BioPharma Group PLC ADR (MREO)
Mereo BioPharma Group PLC ADR (NASDAQ:MREO) has a market capitalization of $48.79 Million ($48.79 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #22070 globally and #4917 in its home market, demonstrating a -9.50% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Mereo BioPharma Group PLC ADR's stock price $0.31 by its total outstanding shares 159131701 (159.13 Million). Also see Mereo BioPharma Group PLC ADR assets under control for a full breakdown of the balance sheet.
Mereo BioPharma Group PLC ADR Market Cap History: 2019 to 2026
Mereo BioPharma Group PLC ADR's market capitalization history from 2019 to 2026. Data shows change from $521.95 Million to $46.16 Million (-35.35% CAGR). Also see Mereo BioPharma Group PLC ADR (MREO) cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
Mereo BioPharma Group PLC ADR is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.67 Trillion | 0.00% | #636 of 976 |
|
NASDAQ Composite
IXIC
|
$41.95 Trillion | 0.00% | #2103 of 3165 |
Weight: Mereo BioPharma Group PLC ADR's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Mereo BioPharma Group PLC ADR Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Mereo BioPharma Group PLC ADR's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check current stock price of Mereo BioPharma Group PLC ADR for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
132.62x
Mereo BioPharma Group PLC ADR's market cap is 132.62 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $521.95 Million | $-122.00K | -$44.45 Million | -4278.29x | N/A |
| 2020 | $569.69 Million | $393.00K | -$209.83 Million | 1449.60x | N/A |
| 2021 | $254.61 Million | $49.21 Million | $17.17 Million | 5.17x | 14.83x |
| 2022 | $119.35 Million | $1.51 Million | -$42.22 Million | 79.20x | N/A |
| 2023 | $367.59 Million | $10.00 Million | -$29.47 Million | 36.76x | N/A |
| 2025 | $66.31 Million | $500.00K | -$41.88 Million | 132.62x | N/A |
Competitor Companies of MREO by Market Capitalization
Companies near Mereo BioPharma Group PLC ADR in the global market cap rankings as of September 18, 2026. Review tangible equity quality of Mereo BioPharma Group PLC ADR to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Mereo BioPharma Group PLC ADR by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
Mereo BioPharma Group PLC ADR Historical Marketcap From 2019 to 2026
Between 2019 and today, Mereo BioPharma Group PLC ADR's market cap moved from $521.95 Million to $ 46.16 Million, with a yearly change of -35.35%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $46.16 Million | -30.38% |
| 2025 | $66.31 Million | -88.09% |
| 2024 | $556.96 Million | +51.52% |
| 2023 | $367.59 Million | +208.00% |
| 2022 | $119.35 Million | -53.12% |
| 2021 | $254.61 Million | -55.31% |
| 2020 | $569.69 Million | +9.15% |
| 2019 | $521.95 Million | -- |
End of Day Market Cap According to Different Sources
On Apr 24th, 2026 the market cap of Mereo BioPharma Group PLC ADR was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $48.79 Million USD |
| MoneyControl | $48.79 Million USD |
| MarketWatch | $48.79 Million USD |
| marketcap.company | $48.79 Million USD |
| Reuters | $48.79 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Mereo BioPharma Group PLC ADR
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab, an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for use in the treatment of tumors. The company is also developing Navi… Read more